Title
Category
Credits
Event date
Cost
  • Patient Centered Care
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Introduction and discussion of supportive care programs in a "home away from home" for patients during their cancer journey.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.50 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Frances Collichio, MD, reviews the common and uncommon side effects of immune check point inhibitors. She also discusses the relatively new concept of delayed immune related events.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.25 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Dominique Higgins, MD, PhD, provides an overview of diagnostic criteria for primary CNS brain tumors, and the current approved and investigational treatments that are available and on the horizon.
  • Patient Centered Care
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.50 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Jacob Stein, MD, MPH, reviews several of the most common medical emergencies that arise when caring for patients with cancer. We highlight key aspects of presentation, diagnosis and management, with pearls for clinicians along the way.
  • Patient Centered Care
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 ASRT
  • 1.00 CTR
  • 1.00 Participation
$0.00
Erin Kent, PhD, MSc, and Loretta Muss, RN, BA, discuss how to recruit the caregiver into the patient’s plan of care and understanding the role and the stresses of being an oncology caregiver.
  • Patient Centered Care
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Puneet Singh Jolly, MD, PhD discusses keratinocyte neoplasms are by far the most common malignancy in the world. While surgical treatments remain the most common and most effective therapy, there are numerous emerging non-surgical techniques. We discuss these and the rationale for using such treatments, particularly in specific challenging clinical scenarios.

Pages